Epstein-Barr virus (EBV) is the first identified oncogenic virus without any vaccine or therapeutic. In this review, we summarize (i) the disease burden caused by EBV; (ii) previous EBV vaccine studies and available animal models; (iii) future trends of EBV vaccines development.

We found that the risks of outcomes indicating severe disease were lower or similar for those infected with BA.2 sub-lineage of Omicron, compared to BA.1, after controlling for confounding factors.

Behind Paper： The epidermal CD1c+CD11b+ cDC2s poised in the psoriasis perilesional skin, prepare the tissue and initiate inflammation，co-work with CD207+CD11chi LCs and CD5+ T cells in the psoriatic epidermis.